澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

CHIMERIC THERAPEUTICS LTD

0.003

0.000

成交量：- -

成交额：- -

市值：44.24万

市盈率：0.00

高：0.003

开：0.003

低：0.003

收：0.003

52周最高：0.400

52周最低：0.003

股本：1.47亿

流通股本：2,907.08万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.610

每股收益(LYR):-0.610

净资产收益率：-1290.99%

总资产收益率：-46.75%

市净率：-0.06

市盈率(LYR):0.00

数据加载中...

总览公司新闻资讯公告

体内通路取得进展，Chimeric Therapeutics拟与潜在合作伙伴重启谈判

Chimeric Therapeutics启动战略评估，或出售、授权或合作其CHM CDH17资产与项目

Chimeric Therapeutics Ltd实施重大成本削减措施，预计年度支出将减少约400万澳元

Chimeric Therapeutics Ltd：FY26财务报告预计将包含持续经营重大不确定性

Chimeric Therapeutics 停牌：CDH17临床试验结果公布在即

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/CHM.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.003,"timestamp":1791868320000,"preClose":0.003,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":29070766,"shares":147461982,"eps":-0.6097,"marketStatus":"已收盘","change":0,"latestTime":"10-13 16:12:00 AEDT","open":0.003,"high":0.003,"low":0.003,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.6097,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.003,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CHM.AU","preClose":0.003,"auctionPrice":0.003,"auctionVolume":508333,"auction":1,"marketStatus":"盘前竞价","timestamp":1790811290384}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":29070766,"roa":"-46.75%","roe":"-1290.99%","lyrEps":-0.6097,"shares":147461982,"dividePrice":0,"high":0.003,"amplitude":0,"preClose":0.003,"low":0.003,"week52Low":0.003,"pbRate":"-0.06","psRate":"-2.33","week52High":0.4,"institutionHeld":0,"latestPrice":0.003,"eps":-0.6097,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.6097,"open":0.003,"prevYearClose":0.2,"prevWeekClose":0.003,"prevMonthClose":0.003,"prevQuarterClose":0.003,"fiveDayClose":0.003,"twentyDayClose":0.006,"sixtyDayClose":0.042,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-04-22","symbol":"CHM.AU","defaultRemindTime":1776816000000,"type":"split","dateTimestamp":1776780000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133213709","title":"体内通路取得进展，Chimeric Therapeutics拟与潜在合作伙伴重启谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=1133213709","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133213709?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 07:11","pubTimestamp":1787094670,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd——随着其体内通路不断推进，公司计划重新与潜在合作伙伴展开接触。\n这一动向标志着该生物制药企业在研发管线的关键节点上，正积极寻求外部协作与资源整合，以加速候选疗法的临床转化进程。\n在体内研究数据渐趋成熟的背景下，管理层显然认为，此刻正是重返谈判桌、深化战略联盟的恰当时机。无论是联合开发、授权许可，抑或是更广泛的商业合作，均有可能成为下一步棋局中的选项。\n市场观察人士指出，此类举措往往折射出企业对自身技术平台的信心增强，同时也暗示着其商业化路径正从实验室迈向更广阔的产业舞台。对于关注细胞治疗领域的投资者而言，这一信号无疑值得密切留意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191148680","title":"Chimeric Therapeutics启动战略评估，或出售、授权或合作其CHM CDH17资产与项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1191148680","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191148680?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 07:11","pubTimestamp":1787094668,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics（澳交所代码：CHM）宣布，已启动一项流程，旨在探索出售、对外许可或合作其CHM CDH17资产及相关项目的潜在可能。此举意味着公司正积极评估该资产在市场上的多种发展路径，以最大化其价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106385827","title":"Chimeric Therapeutics Ltd实施重大成本削减措施，预计年度支出将减少约400万澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106385827","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106385827?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 07:10","pubTimestamp":1787094609,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd——重大成本削减计划已正式落地，此举预计将使公司年度化支出缩减大约400万澳元。\n这家生物医药企业正积极调整运营策略，以优化财务结构。通过一系列精简措施，公司力求在维持核心研发管线推进的同时，显著降低整体资金消耗速率。\n此番成本控制动作，不仅反映了管理层对当前市场环境的审慎态度，也彰显了其提升资本效率、延长现金流跑道以支撑后续关键里程碑的决心。业界普遍认为，此类战略性节流举措，对于处于临床阶段、亟需平衡研发投入与财务稳健的生物科技公司而言，至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121509471","title":"Chimeric Therapeutics Ltd：FY26财务报告预计将包含持续经营重大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1121509471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121509471?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 07:10","pubTimestamp":1787094609,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd（CHIMERIC THERAPEUTICS LTD）发布公告称，其2026财年财务报告预计将涵盖一项与持续经营相关的重大不确定性。这一消息揭示了公司在未来运营持续性方面可能面临的严峻挑战。根据公告内容，该不确定性因素的存在，可能对公司维持正常业务运作的能力构成实质性影响。投资者需密切关注这一动态，以评估公司未来的财务稳健性及可持续经营前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127776234","title":"Chimeric Therapeutics 停牌：CDH17临床试验结果公布在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1127776234","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127776234?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 07:55","pubTimestamp":1786924508,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics（股票代码：CHM.AU）宣布其证券已进入停牌状态。此次停牌，旨在等待一项关于CDH17临床试验结果的公告发布。市场正屏息以待，这份公告将为投资者揭示关键的试验数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}